

VASTox plc
(“VASTox” or “the Company”)

**VASTOX TO PRESENT DATA FROM DUCHENNE MUSCULAR DYSTROPHY
DRUG DISCOVERY PROGRAMME AT LEADING INTERNATIONAL
CONFERENCE**

Oxford, UK, 30 April 2007 – VASTox plc (AIM: VOX), a leading UK biotechnology company, announces that Professor Kay Davies, co-founder of VASTox and Chair of the Company’s Scientific Advisory Board, will be presenting at “The 20th Anniversary of the DMD Gene Discovery: Impact on Muscle, Disease and Therapy” conference, which will take place on 3-5 May 2007 in Ottawa, Canada.

This conference, which is being co-sponsored by VASTox, will bring together the world’s pre-eminent scientists in the field of musculoskeletal disease research from commercial and academic backgrounds. Prof. Davies, a leading expert in Duchenne Muscular Dystrophy (“DMD”), will present data from VASTox’s unique, disease modifying approach for a DMD therapy at the conference. Also in attendance from VASTox will be the Company’s Chief Scientific Officer, Richard Storer, PhD and Director of Programmes, Jon Tinsley, PhD.

- ends -

For more information please contact:

VASTox

Steven Lee, PhD, Chief Executive Officer
Richard Storer, PhD, Chief Scientific Officer

Tel: +44 (0)1235 443951

Citigate Dewe Rogerson

Mark Swallow / David Dible / Valerie Auffray

Tel: +44 (0)207 638 9571

About VASTox plc

VASTox is a leading UK biotechnology company that discovers and develops proprietary new drugs. The Company’s internal drug development programmes are underpinned by its advanced chemistry and drug screening (chemical genomics) technology platforms, which it also provides on a collaborative or fee-for-service basis to the pharmaceutical industry.

VASTox has a broad range of drug discovery programmes in the clinical, pre-clinical and discovery stages of development, which target serious diseases with a high unmet medical need. These therapeutic areas include neuro-disorders (neurodegenerative and neuromuscular), anti-infectives, ophthalmic diseases, oncology and regenerative medicines.

VASTox’s in-house drug development capabilities combine world-class expertise in both medicinal and carbohydrate chemistry with high-volume, high-content screening using its proprietary zebrafish and fruitfly technologies (chemical genomics). These whole organism screens have the potential to dramatically decrease the time and

cost of drug discovery and development by delivering data that are highly predictive of the efficacy and toxicity of potential drug compounds in humans.

The company listed on the AIM market of the London Stock Exchange in October 2004 – symbol: VOX

Further information about the company is available at www.vastox.com

This document contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "anticipates", "intends", "plans", "seeks", "believes", "estimates", "expects" and similar references to future periods, or by the inclusion of forecasts or projections.

Forward-looking statements are based on the Company's current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. The Company's actual results may differ materially from those contemplated by the forward-looking statements. The Company cautions you therefore that you should not rely on any of these forward-looking statements as statements of historical fact or as guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements and regional, national, global political, economic, business, competitive, market and regulatory conditions.